Literature DB >> 22079330

Development of IgA nephropathy-like glomerulonephritis associated with Wiskott-Aldrich syndrome protein deficiency.

M Shimizu1, N P Nikolov, K Ueno, K Ohta, R M Siegel, A Yachie, F Candotti.   

Abstract

Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder caused by mutations in the WAS gene. Glomerulonephritis is a frequent complication, however, histopathological data from affected patients is scarce because the thrombocytopenia that affects most patients is a contraindication to renal biopsies. We found that WASp-deficient mice develop proliferative glomerulonephritis reminiscent of human IgA nephropathy (IgAN). We examined whether increased aberrant IgA production is associated with the development of glomerulonephritis in WASp-deficient mice. Serum IgA and IgA production by splenic B cells was increased in WASp-deficient mice compared to wild-type (WT) mice. A lectin-binding study revealed a reduced ratio of sialylated and galactosylated IgA in the sera from old WASp-deficient mice. Circulating IgA-containing immune complexes showed significantly higher titers in WASp-deficient mice compared to WT mice. These results indicate that the increased IgA production and aberrant glycosylation of IgA may be critically involved in the pathogenesis of glomerulonephritis in WAS.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079330      PMCID: PMC3273668          DOI: 10.1016/j.clim.2011.10.001

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  39 in total

1.  Development of immunoglobulin A nephropathy- like disease in beta-1,4-galactosyltransferase-I-deficient mice.

Authors:  Toshikazu Nishie; Osamu Miyaishi; Haruhito Azuma; Akihiko Kameyama; Chie Naruse; Noriyoshi Hashimoto; Hitoshi Yokoyama; Hisashi Narimatsu; Takashi Wada; Masahide Asano
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

2.  Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.

Authors:  Hitoshi Suzuki; Run Fan; Zhixin Zhang; Rhubell Brown; Stacy Hall; Bruce A Julian; W Winn Chatham; Yusuke Suzuki; Robert J Wyatt; Zina Moldoveanu; Jeannette Y Lee; James Robinson; Milan Tomana; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2009-05-26       Impact factor: 14.808

3.  IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells.

Authors:  Jan Novak; Milan Tomana; Karel Matousovic; Rhubell Brown; Stacy Hall; Lea Novak; Bruce A Julian; Robert J Wyatt; Jiri Mestecky
Journal:  Kidney Int       Date:  2005-02       Impact factor: 10.612

4.  Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein.

Authors:  Deanna D Nguyen; Michel H Maillard; Vinicius Cotta-de-Almeida; Emiko Mizoguchi; Christoph Klein; Ivan Fuss; Cathryn Nagler; Atsushi Mizoguchi; Atul K Bhan; Scott B Snapper
Journal:  Gastroenterology       Date:  2007-07-12       Impact factor: 22.682

Review 5.  Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome.

Authors:  Marita Bosticardo; Francesco Marangoni; Alessandro Aiuti; Anna Villa; Maria Grazia Roncarolo
Journal:  Blood       Date:  2009-04-07       Impact factor: 22.113

Review 6.  The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy.

Authors:  Jonathan Barratt; Alice C Smith; John Feehally
Journal:  Nephrology (Carlton)       Date:  2007-06       Impact factor: 2.506

7.  IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1.

Authors:  Hitoshi Suzuki; Zina Moldoveanu; Stacy Hall; Rhubell Brown; Huong L Vu; Lea Novak; Bruce A Julian; Milan Tomana; Robert J Wyatt; Jeffrey C Edberg; Graciela S Alarcón; Robert P Kimberly; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

8.  Abnormal O-glycosylation of CD43 may account for some features of Wiskott-Aldrich syndrome.

Authors:  S Khan; S Holding; P C Doré; W A C Sewell
Journal:  Med Hypotheses       Date:  2007-07-30       Impact factor: 1.538

9.  Toll-like receptor 9 affects severity of IgA nephropathy.

Authors:  Hitoshi Suzuki; Yusuke Suzuki; Ichiei Narita; Masashi Aizawa; Masao Kihara; Takahiro Yamanaka; Tatsuya Kanou; Hiroyasu Tsukaguchi; Jan Novak; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Am Soc Nephrol       Date:  2008-09-05       Impact factor: 10.121

10.  Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.

Authors:  Z Moldoveanu; R J Wyatt; J Y Lee; M Tomana; B A Julian; J Mestecky; W-Q Huang; S R Anreddy; S Hall; M C Hastings; K K Lau; W J Cook; J Novak
Journal:  Kidney Int       Date:  2007-03-07       Impact factor: 10.612

View more
  11 in total

1.  The clinical features of autoimmunity in 53 patients with Wiskott-Aldrich syndrome in China: a single-center study.

Authors:  Nan Chen; Zhi-Yong Zhang; Da-Wei Liu; Wei Liu; Xue-Mei Tang; Xiao-Dong Zhao
Journal:  Eur J Pediatr       Date:  2015-04-16       Impact factor: 3.183

2.  Immune Complex-Mediated Glomerulonephritis in a Patient with Wiskott-Aldrich Syndrome.

Authors:  Tomonari Shigemura; Yozo Nakazawa; Hisashi Shimojo; Norimoto Kobayashi; Kazunaga Agematsu
Journal:  J Clin Immunol       Date:  2016-03-10       Impact factor: 8.317

Review 3.  Wiskott-Aldrich syndrome with IgA nephropathy: a case report and literature review.

Authors:  Chia-Hung Liu; Kang-Hsi Wu; Tze-Yi Lin; Chang-Ching Wei; Ching-Yuang Lin; Xian-Xiu Chen; Wen-I Lee
Journal:  Int Urol Nephrol       Date:  2012-05-01       Impact factor: 2.370

4.  Allogeneic bone marrow transplantation appears to ameliorate IgA nephropathy in a patient with X-linked thrombocytopenia.

Authors:  Akihiro Hoshino; Masaki Shimizu; Hiroyoshi Matsukura; Hisano Sakaki-Nakatsubo; Keiko Nomura; Toshio Miyawaki; Hirokazu Kanegane
Journal:  J Clin Immunol       Date:  2013-11-12       Impact factor: 8.317

5.  Aberrant glycosylation of IgA in Wiskott-Aldrich syndrome and X-linked thrombocytopenia.

Authors:  Masaki Shimizu; Hirokazu Kanegane; Taizo Wada; Yaeko Motoyoshi; Tomohiro Morio; Fabio Candotti; Akihiro Yachie
Journal:  J Allergy Clin Immunol       Date:  2012-10-26       Impact factor: 10.793

6.  Autoimmunity in wiskott-Aldrich syndrome: an unsolved enigma.

Authors:  Marco Catucci; Maria Carmina Castiello; Francesca Pala; Marita Bosticardo; Anna Villa
Journal:  Front Immunol       Date:  2012-07-18       Impact factor: 7.561

Review 7.  Unbalanced Immune System: Immunodeficiencies and Autoimmunity.

Authors:  Giuliana Giardino; Vera Gallo; Rosaria Prencipe; Giovanni Gaudino; Roberta Romano; Marco De Cataldis; Paola Lorello; Loredana Palamaro; Chiara Di Giacomo; Donatella Capalbo; Emilia Cirillo; Roberta D'Assante; Claudio Pignata
Journal:  Front Pediatr       Date:  2016-10-06       Impact factor: 3.418

8.  Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells.

Authors:  Francesca Prete; Marco Catucci; Mayrel Labrada; Stefania Gobessi; Maria Carmina Castiello; Elisa Bonomi; Alessandro Aiuti; William Vermi; Caterina Cancrini; Ayse Metin; Sophie Hambleton; Robbert Bredius; Luigi Daniele Notarangelo; Mirjam van der Burg; Ulrich Kalinke; Anna Villa; Federica Benvenuti
Journal:  J Exp Med       Date:  2013-01-21       Impact factor: 14.307

9.  Age-Dependent Defects of Regulatory B Cells in Wiskott-Aldrich Syndrome Gene Knockout Mice.

Authors:  Tadafumi Yokoyama; Ayumi Yoshizaki; Karen L Simon; Martha R Kirby; Stacie M Anderson; Fabio Candotti
Journal:  PLoS One       Date:  2015-10-08       Impact factor: 3.240

10.  Exacerbated experimental arthritis in Wiskott-Aldrich syndrome protein deficiency: modulatory role of regulatory B cells.

Authors:  Gerben Bouma; Natalie A Carter; Mike Recher; Dessislava Malinova; Marsilio Adriani; Luigi D Notarangelo; Siobhan O Burns; Claudia Mauri; Adrian J Thrasher
Journal:  Eur J Immunol       Date:  2014-07-15       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.